As a national law firm that practices defective drug and personal injury litigation, Carey Danis & Lowe has worked on numerous cases where a pharmaceutical company misrepresented a product, and in doing so, ignored patient health and safety.
Even though their products have proven to be harmful in some cases, a recent Washington Post article on off-label drug marketing revealed that pharmaceutical companies often declare a violation of freedom of speech in regards to overly strict marketing regulations.
Johnson & Johnson conducted a misleading marketing campaign for their anti-psychotic drug, Risperdal. Approved by the U.S. Food and Drug Administration (FDA) to treat adults with schizophrenia, Johnson & Johnson marketed the drug for use in children.
According to the U.S. Department of Justice, Johnson & Johnson, and their subsidiary, Janssen, were aware of the dangers the drug Risperdal posed when used by children. Even so, company representatives marketed the drug to mental health professionals who worked with children.
As a result of their misleading Risperdal marketing campaign, Johnson & Johnson was ordered in 2013 by the U.S. Department of Justice to pay a $2.2 billion fine.
When used by children and adolescents, Risperdal has been known to cause male breast growth, also known as gynecomastia, due to the drug triggering the production of the hormone prolactin. For some patients who have suffered from gynecomastia as a Risperdal side effect, they have also dealt with decreased psychological and emotional well being as a result of physical changes.
Carey Danis & Lowe represents patients who have been injured by Risperdal and other defective drugs. Our defective drug lawyers are offering free initial case evaluations, and are available to discuss legal options and compensation eligibility.Pharmaceutical litigation, Risperdal